Búsqueda | Portal de Búsqueda de la BVS

1.

Synovial tissue hypoxia and inflammation in vivo.

Ng, C T; Biniecka, M; Kennedy, A; McCormick, J; Fitzgerald, O; Bresnihan, B; Buggy, D; Taylor, C T; O'Sullivan, J; Fearon, U; Veale, D J.

Ann Rheum Dis ; 69(7): 1389-95, 2010 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-20439288

2.

Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis.

Martin, J; Walsh, C; Gibbs, A; McDonnell, T; Fearon, U; Keane, J; Codd, M B; Dodd, J; Veale, D; Fitzgerald, O; Bresnihan, B.

Ann Rheum Dis ; 69(1): 181-5, 2010 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-19176545

3.

EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis.

Zhang, W; Doherty, M; Peat, G; Bierma-Zeinstra, M A; Arden, N K; Bresnihan, B; Herrero-Beaumont, G; Kirschner, S; Leeb, B F; Lohmander, L S; Mazières, B; Pavelka, K; Punzi, L; So, A K; Tuncer, T; Watt, I; Bijlsma, J W.

Ann Rheum Dis ; 69(3): 483-9, 2010 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-19762361

4.

Melanoma inhibitory activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis.

Vandooren, B; Cantaert, T; van Lierop, M-J; Bos, E; De Rycke, L; Veys, E M; De Keyser, F; Bresnihan, B; Luyten, F P; Verdonk, P C; Tak, P P; Boots, A H; Baeten, D.

Ann Rheum Dis ; 68(6): 1044-50, 2009 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-18633128

5.

Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database.

Sokka, T; Kautiainen, H; Pincus, T; Toloza, S; da Rocha Castelar Pinheiro, G; Lazovskis, J; Hetland, M L; Peets, T; Immonen, K; Maillefert, J F; Drosos, A A; Alten, R; Pohl, C; Rojkovich, B; Bresnihan, B; Minnock, P; Cazzato, M; Bombardieri, S; Rexhepi, S; Rexhepi, M; Andersone, D; Stropuviene, S; Huisman, M; Sierakowski, S; Karateev, D; Skakic, V; Naranjo, A; Baecklund, E; Henrohn, D; Gogus, F; Badsha, H; Mofti, A; Taylor, P; McClinton, C; Yazici, Y.

Ann Rheum Dis ; 68(11): 1666-72, 2009 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-19643759

6.

Differential expression of syndecans and glypicans in chronically inflamed synovium.

Patterson, A M; Cartwright, A; David, G; Fitzgerald, O; Bresnihan, B; Ashton, B A; Middleton, J.

Ann Rheum Dis ; 67(5): 592-601, 2008 May.

Artículo en Inglés | MEDLINE | ID: mdl-17545191

7.

Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy.

Walsh, C A E; Fearon, U; FitzGerald, O; Veale, D J; Bresnihan, B.

Clin Exp Rheumatol ; 26(4): 656-8, 2008.

Artículo en Inglés | MEDLINE | ID: mdl-18799100

8.

Suppressor function of peripheral blood mononuclear cells in normal individuals and in patients with systemic lupus erythematosus.

Bresnihan, B; Jasin, H E.

J Clin Invest ; 59(1): 106-16, 1977 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-830659

9.

Unregulated prescribing of anti-tumour necrosis factor agents does not mean inappropriate prescribing.

Ng, C T; Radovits, B J; Kievit, W; Fransen, J; van Riel, P L C M; FitzGerald, O; Veale, D J; Bresnihan, B.

Ann Rheum Dis ; 69(1): 313-4, 2010 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-20007623

10.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.

Furst, D E; Keystone, E C; Fleischmann, R; Mease, P; Breedveld, F C; Smolen, J S; Kalden, J R; Braun, J; Bresnihan, B; Burmester, G R; De Benedetti, F; Dörner, T; Emery, P; Gibofsky, A; Kavanaugh, A; Kirkham, B; Schiff, M H; Sieper, J; Singer, N; Van Riel, P L C M; Weinblatt, M E; Weisman, M H; Winthrop, K.

Ann Rheum Dis ; 69 Suppl 1: i2-29, 2010 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-19995740

11.

Doppler echocardiographic evidence of left ventricular diastolic dysfunction in ankylosing spondylitis.

Crowley, J J; Donnelly, S M; Tobin, M; FitzGerald, O; Bresnihan, B; Maurer, B J; Quigley, P J.

Am J Cardiol ; 71(15): 1337-40, 1993 Jun 01.

Artículo en Inglés | MEDLINE | ID: mdl-8498377

12.

The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis.

Bresnihan, B.

Semin Arthritis Rheum ; 30(5 Suppl 2): 17-20, 2001 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-11357167

13.

Lymphedema of the upper limb in patients with psoriatic arthritis.

Mulherin, D M; FitzGerald, O; Bresnihan, B.

Semin Arthritis Rheum ; 22(5): 350-6, 1993 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-8511598

14.

Analysis of cell populations in rheumatoid arthritis synovial tissues.

Yanni, G; Whelan, A; Feighery, C; Bresnihan, B.

Semin Arthritis Rheum ; 21(6): 393-9, 1992 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-1626285

15.

Interleukin-1 receptor antagonist.

Bresnihan, B; Cunnane, G.

Rheum Dis Clin North Am ; 24(3): 615-28, 1998 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-9710890

16.

Adhesion molecules in untreated inflammatory arthritis: synovial expression and levels in synovial fluid and serum [corrected].

Mulherin, D M; Veale, D J; Belch, J J; Bresnihan, B; Fitzgerald, O.

QJM ; 89(3): 195-203, 1996 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-8731563

17.

The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

Bresnihan, B.

BioDrugs ; 15(2): 87-97, 2001.

Artículo en Inglés | MEDLINE | ID: mdl-11437678

18.

Diflunisal in the treatment of osteoarthrosis: a double-blind study comparing diflunisal with ibuprofen.

Bresnihan, B; Hughes, G; Essigman, W K.

Curr Med Res Opin ; 5(7): 556-61, 1978.

Artículo en Inglés | MEDLINE | ID: mdl-359250

19.

Anakinra as a new therapeutic option in rheumatoid arthritis: clinical results and perspectives.

Bresnihan, B.

Clin Exp Rheumatol ; 20(5 Suppl 27): S32-4, 2002.

Artículo en Inglés | MEDLINE | ID: mdl-14989427

20.

Disease-modifying anti-rheumatic drug therapy and structural damage in early rheumatoid arthritis.

Mullan, R H; Bresnihan, B.

Clin Exp Rheumatol ; 21(5 Suppl 31): S158-64, 2003.

Artículo en Inglés | MEDLINE | ID: mdl-14969069

Portal de Búsqueda de la BVS

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Synovial tissue hypoxia and inflammation in vivo.

Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis.

EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis.

Melanoma inhibitory activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis.

Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database.

Differential expression of syndecans and glypicans in chronically inflamed synovium.

Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy.

Suppressor function of peripheral blood mononuclear cells in normal individuals and in patients with systemic lupus erythematosus.

Unregulated prescribing of anti-tumour necrosis factor agents does not mean inappropriate prescribing.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.

Doppler echocardiographic evidence of left ventricular diastolic dysfunction in ankylosing spondylitis.

The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis.

Lymphedema of the upper limb in patients with psoriatic arthritis.

Analysis of cell populations in rheumatoid arthritis synovial tissues.

Interleukin-1 receptor antagonist.

Adhesion molecules in untreated inflammatory arthritis: synovial expression and levels in synovial fluid and serum [corrected].

The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

Diflunisal in the treatment of osteoarthrosis: a double-blind study comparing diflunisal with ibuprofen.

Anakinra as a new therapeutic option in rheumatoid arthritis: clinical results and perspectives.

Disease-modifying anti-rheumatic drug therapy and structural damage in early rheumatoid arthritis.